165 related articles for article (PubMed ID: 29878738)
1. [Progress in regulation of drug transporters and metabolic enzymes by resveratrol].
Jia YM; Liu ZH; Liu KX
Yao Xue Xue Bao; 2016 Jun; 51(6):860-5. PubMed ID: 29878738
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Drug-Drug Interaction Evaluation of GalNAc Conjugated siRNAs Against CYP450 Enzymes and Transporters.
Ramsden D; Wu JT; Zerler B; Iqbal S; Jiang J; Clausen V; Aluri K; Gu Y; Dennin S; Kim J; Chong S
Drug Metab Dispos; 2019 Oct; 47(10):1183-1194. PubMed ID: 31270142
[TBL] [Abstract][Full Text] [Related]
3. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
4. Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors.
Hyrsova L; Vanduchova A; Dusek J; Smutny T; Carazo A; Maresova V; Trejtnar F; Barta P; Anzenbacher P; Dvorak Z; Pavek P
Toxicol Lett; 2019 Jan; 300():81-91. PubMed ID: 30394306
[TBL] [Abstract][Full Text] [Related]
5. Regulation of brain drug metabolizing enzymes and transporters by nuclear receptors.
Xu D; Huang S; Wang H; Xie W
Drug Metab Rev; 2018 Nov; 50(4):407-414. PubMed ID: 30501435
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug Interactions of Angiotensin Converting Enzyme Inhibitors Mediated by Metabolizing Enzymes and Transporters.
Sun P; Liu K
Curr Drug Metab; 2018; 19(13):1119-1129. PubMed ID: 30062958
[TBL] [Abstract][Full Text] [Related]
7. Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions.
Lu C; Liao M; Cohen L; Xia CQ
Curr Drug Discov Technol; 2010 Sep; 7(3):199-222. PubMed ID: 20843292
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases.
Liu B; Luo F; Luo X; Duan S; Gong Z; Peng J
Curr Drug Metab; 2018; 19(7):568-576. PubMed ID: 29299983
[TBL] [Abstract][Full Text] [Related]
9. [Advances in the study of enzymes and transporters-mediated pharmacokinetic mechanism for herb-drug interaction].
Liu Q; Liu KX
Yao Xue Xue Bao; 2015 Apr; 50(4):406-12. PubMed ID: 26223121
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of pharmacokinetic drug-drug interactions].
Levêque D; Lemachatti J; Nivoix Y; Coliat P; Santucci R; Ubeaud-Séquier G; Beretz L; Vinzio S
Rev Med Interne; 2010 Feb; 31(2):170-9. PubMed ID: 19740579
[TBL] [Abstract][Full Text] [Related]
11. Phenotyping drug disposition in oncology.
Opdam FL; Gelderblom H; Guchelaar HJ
Cancer Treat Rev; 2012 Oct; 38(6):715-25. PubMed ID: 22226243
[TBL] [Abstract][Full Text] [Related]
12. [Advance of studies on effect of resveratrol on activity of cytochrome P450].
Lu Y; Huang ZJ; Yuan H
Zhongguo Zhong Yao Za Zhi; 2013 Mar; 38(5):653-6. PubMed ID: 23724668
[TBL] [Abstract][Full Text] [Related]
13. The potential of Sutherlandia frutescens for herb-drug interaction.
Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
[TBL] [Abstract][Full Text] [Related]
14. Role of resveratrol in regulation of membrane transporters and integrity of human erythrocytes.
Pandey KB; Rizvi SI
Biochem Biophys Res Commun; 2014 Oct; 453(3):521-6. PubMed ID: 25285638
[TBL] [Abstract][Full Text] [Related]
15. [The drug-drug interaction mediated by efflux transporters and CYP450 enzymes].
Wang C; Liu KX
Yao Xue Xue Bao; 2014 May; 49(5):590-5. PubMed ID: 25151726
[TBL] [Abstract][Full Text] [Related]
16. Interplay of Drug-Metabolizing Enzymes and Transporters in Drug Absorption and Disposition.
Shi S; Li Y
Curr Drug Metab; 2014; 15(10):915-41. PubMed ID: 25828591
[TBL] [Abstract][Full Text] [Related]
17. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
[TBL] [Abstract][Full Text] [Related]
18. Application of in vitro CYP and transporter assays to predict clinical drug-drug interactions.
Volpe DA; Balimane PV
Bioanalysis; 2018 May; 10(9):619-623. PubMed ID: 29768028
[No Abstract] [Full Text] [Related]
19. Evaluation of herb-drug interaction of a polyherbal Ayurvedic formulation through high throughput cytochrome P450 enzyme inhibition assay.
Pandit S; Kanjilal S; Awasthi A; Chaudhary A; Banerjee D; Bhatt BN; Narwaria A; Singh R; Dutta K; Jaggi M; Singh AT; Sharma N; Katiyar CK
J Ethnopharmacol; 2017 Feb; 197():165-172. PubMed ID: 27457692
[TBL] [Abstract][Full Text] [Related]
20. Alterations of drug-metabolizing enzymes and transporters under diabetic conditions: what is the potential clinical significance?
Chen F; Li DY; Zhang B; Sun JY; Sun F; Ji X; Qiu JC; Parker RB; Laizure SC; Xu J
Drug Metab Rev; 2018 Aug; 50(3):369-397. PubMed ID: 30221555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
